Phaseline

Targets › IL13RA2

IL13RA2 (Interleukin-13 receptor subunit alpha-2): drug programs, companies and trials

6 programs from 4 companies in 14 trials: 14 Phase 1; Oncology; next expected readout Jan 2027.

Cell surface receptor that plays a role in the regulation of IL-13-mediated responses. Functions as a decoy receptor that inhibits IL-13- and IL-4-mediated signal transduction via the JAK-STAT pathway and thereby modulates immune responses and inflammation. (UniProt, Q14627)

Open in Phaseline: the race on IL13RA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterIL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expr
IL13Rα2-specific CAR-T cells with 41BB co-stimulatory domain and truncated CD19 marker
IL13RA2Phase 1Ependymoma; Malignant Brain NeoplasmJan 2027
Beijing BiotechEB-G3B7-NK dual-target CAR-NK cells
Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr
CD276, MSLN, EGFR, ERBB2, IL13RA2Phase 1Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) …Feb 2027
City of Hope Medical CenterIL13Ra2-specific CAR Tcm cells
CAR-T cell expressing IL13 ligand binding domain targeted to IL13Ra2
IL13RA2Phase 1Recurrent GlioblastomaMay 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineEPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy
Bispecific CAR-T cell therapy targeting B7H3 and IL13Ra2
B7H3, IL13RA2Phase 1Refractory GlioblastomaDec 2027
City of Hope Medical CenterIL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-exp
IL13RA2-targeted CAR-T cell therapy with 4-1BB co-stimulation and truncated CD19
IL13RA2Phase 1Recurrent Glioblastoma–
Anusha KalbasiIL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-exp
IL13RA2-specific CAR-T cell therapy with 4-1BB co-stimulatory domain and truncated CD19
IL13RA2Phase 1Metastatic Malignant Solid Neoplasm–

Conditions

Recurrent Glioblastoma (3) Non-Small Cell Lung Cancer (2) Ependymoma (1) Malignant Brain Neoplasm (1) Metastatic Malignant Solid Neoplasm (1) Breast Cancer (Locally Advanced or Metastatic) (1) Glioblastoma (1) Advanced Hepatocellular Carcinoma (HCC) (1) Breast Cancer (Advanced/Metastatic) (1) Malignant Glioma (1) Refractory Glioblastoma (1)

Modalities

mixed (4), other (2)

Companies

City of Hope Medical Center (3) Anusha Kalbasi (1) Beijing Biotech (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Related targets

CD276 (1) MSLN (1) EGFR (1) ERBB2 (1) B7H3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.